Pretreatment characteristics
Characteristic . | No As2O3 . | As2O3 . | ||
---|---|---|---|---|
n . | (%) . | n . | (%) . | |
Eligible patients | 237 | 244 | ||
Age, y | ||||
15-60 | 197 | (83) | 207 | (85) |
> 60 | 40 | (17) | 37 | (15) |
Sex | ||||
Male | 124 | (52) | 123 | (50) |
Female | 113 | (48) | 121 | (50) |
Race | ||||
White | 196 | (83) | 196 | (80) |
African American | 14 | (6) | 19 | (8) |
Hispanic | 10 | (4) | 7 | (3) |
Other | 17 | (7) | 22 | (9) |
Performance status | ||||
0 | 91 | (38) | 94 | (39) |
1 | 102 | (43) | 89 | (36) |
2 | 26 | (11) | 36 | (15) |
3 or 4 | 11 | (5) | 14 | (6) |
Unknown | 7 | (3) | 11 | (4) |
Risk group* | ||||
Low | 67 | (28) | 69 | (28) |
Intermediate | 112 | (47) | 120 | (49) |
High | 58 | (25) | 55 | (23) |
Peripheral blood, median (range) | ||||
WBC, ×109/L | 2.2 | (0.2-117.4) | 2.4 | (0.2-138.6) |
Platelets, ×109/L | 29.5 | (1.0-221) | 30.0 | (3.0-232) |
Hemoglobin, g/dL | 9.4 | (6.0-13.7) | 9.0 | (4.3-14.5) |
Characteristic . | No As2O3 . | As2O3 . | ||
---|---|---|---|---|
n . | (%) . | n . | (%) . | |
Eligible patients | 237 | 244 | ||
Age, y | ||||
15-60 | 197 | (83) | 207 | (85) |
> 60 | 40 | (17) | 37 | (15) |
Sex | ||||
Male | 124 | (52) | 123 | (50) |
Female | 113 | (48) | 121 | (50) |
Race | ||||
White | 196 | (83) | 196 | (80) |
African American | 14 | (6) | 19 | (8) |
Hispanic | 10 | (4) | 7 | (3) |
Other | 17 | (7) | 22 | (9) |
Performance status | ||||
0 | 91 | (38) | 94 | (39) |
1 | 102 | (43) | 89 | (36) |
2 | 26 | (11) | 36 | (15) |
3 or 4 | 11 | (5) | 14 | (6) |
Unknown | 7 | (3) | 11 | (4) |
Risk group* | ||||
Low | 67 | (28) | 69 | (28) |
Intermediate | 112 | (47) | 120 | (49) |
High | 58 | (25) | 55 | (23) |
Peripheral blood, median (range) | ||||
WBC, ×109/L | 2.2 | (0.2-117.4) | 2.4 | (0.2-138.6) |
Platelets, ×109/L | 29.5 | (1.0-221) | 30.0 | (3.0-232) |
Hemoglobin, g/dL | 9.4 | (6.0-13.7) | 9.0 | (4.3-14.5) |
Low risk group, WBC ≤ 10 and platelets > 40; intermediate, WBC ≤ 10 and platelets ≤ 40; and high, WBC > 10.